Lenalidomide plus dexamethasone as first-line therapy in transplant-ineligible patients with multiple myeloma

Final results of the prospective, non-interventional study FIRST-NIS and comparison with the FIRST Pivotal phase III clinical trial

The FIRST-NIS study confirms that lenalidomide and low-dose dexamethasone (Rd) is an effective, safe frontline treatment for transplant-ineligible multiple myeloma in real-world settings. Despite a predominantly elderly population, outcomes mirrored pivotal trials, with maintained quality of life. The G8-Geriatric Assessment proved useful for predicting long-term clinical outcomes in these patients.